Physician profile
Christopher George
NPI 1881646156
$1,142.61
in general payments reported to CMS, 2019-2025
23 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $45.32 · 2021: $11.92 · 2022: $228 · 2023: $195 · 2024: $164 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.74 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $111.83 | 2022-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $93.65 | 2023 | Verzenio |
| Sirtex Medical INC | $87.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $86.40 | 2022-2025 | |
| Glaxosmithkline, LLC. | $80.81 | 2025 | Ojjaara |
| Janssen Biotech, INC. | $74.27 | 2019-2022 | |
| Inari Medical, INC. | $57.86 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Gilead Sciences, INC. | $57.36 | 2021-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $41.82 | 2024 | Krazati |
| Tersera Therapeutics LLC | $39.35 | 2025 | Zoladex |
| Merck Sharp & Dohme LLC | $32.56 | 2019-2020 | |
| Celgene Corporation | $32.38 | 2022 | |
| Daiichi Sankyo INC. | $26.77 | 2025 | Enhertu |
| Array Biopharma INC | $23.99 | 2024 | Lorbrena, Mektovi, Braftovi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.71 | 2022 | |
| Medtronic, INC. | $21.46 | 2022 | |
| Csl Behring | $20.28 | 2022 | |
| Ge Healthcare | $20.07 | 2022 | |
| Pharmaessentia USA Corporation | $19.78 | 2024 | Besremi |
| Pfizer INC. | $18.36 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $16.00 | 2019 | |
| Taiho Oncology, INC. | $14.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.